摘要
目的探讨重组人促血小板生成素治疗急性白血病化疗后血小板减少症的效果。方法选取2019年1月至2021年1月佛山市第一人民医院血液淋巴瘤科的60例急性白血病化疗后血小板减少症患者作为研究对象,采用计算机双色球分组法将其分为观察组(30例)和对照组(30例)。观察组患者采用重组人促血小板生成素治疗,对照组患者采用重组人白介素-11治疗。比较两组患者的血小板改善时间、治疗前后血小板水平、用药不良反应。结果观察组患者治疗后的血小板低于50×10^(9)/L持续时间、血小板恢复至70×10^(9)/L持续时间短于对照组,差异有统计学意义(P<0.05);两组患者治疗后的血小板水平高于本组治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的血小板水平高于对照组,差异有统计学意义(P<0.05);观察组患者的用药不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论在急性白血病化疗后血小板减少症患者的治疗中,重组人促血小板生成素的应用效果显著,安全性佳,值得临床应用。
Objective To investigate the effect of Recombinant Human Thrombopoietin in the treatment of acute leukemia with thrombocytopenia after chemotherapy.Methods A total of 60 acute leukemia patients with thrombocytopenia after chemotherapy in the Department of Hematologic Lymphoma of the First People′s Hospital of Foshan City from January 2019 to January 2021 were selected as the study subjects,and they were divided into observation group(30 cases)and control group(30 cases)by computer two-color ball grouping method.The patients in the observation group were treated with Recombinant Human Thrombopoietin,and the patients in the control group were treated with Recombinant Human Interleukin-11.The platelet improvement time,platelet levels before and after treatment and adverse drug reactions were compared between the two groups.Results The times of duration of of platelet index below 50×10^(9)/L and platelet index recovery to 70×10^(9)/L in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).The level of platelet in the two groups after treatment were higher than those before treatment,the differences were statistically significant(P<0.05).The level of platelet in observation group was higher than that in the control group after treatment,the difference was statistically significant(P<0.05).The total incidence of adverse drug reactions in observation group was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion Recombinant Human Thrombopoietin is effective and safe in the treatment of acute leukemia with thrombocytopenia after chemotherapy.
作者
戚永磊
赵莹
QI Yonglei;ZHAO Ying(Department of Hematology and Lymphoma,the First People′s Hospital of Foshan City,Guangdong Province,Foshan528000,China)
出处
《中国当代医药》
CAS
2022年第14期90-92,共3页
China Modern Medicine
基金
广东省佛山市卫生和计生局医学科研课题(20190027)。
